Management of Kidney Transplant Immunosuppression
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".
Deadline for manuscript submissions: closed (20 February 2024) | Viewed by 959
Special Issue Editors
Interests: kidney transplantation; management of highly sensitized patients; management of recipients with failing transplants; post-transplant viral infections (CMV and BKV); immune-mediated kidney disease; clinical trials
Special Issue Information
Dear Colleagues,
Kidney transplantation is transformative, resulting in significant improvements in both quality of life and life expectancy compared to dialysis. However, transplant recipients must take drugs to suppress their immune system. These include induction treatment at the time of transplantation followed by lifelong maintenance treatment. A challenge for patients and clinicians is the balance between sufficient immunosuppression to prevent rejection, and the emergence of opportunistic infections and malignancy because of over-immunosuppression. This has led to a search for a more personalised approach, including both novel therapies and monitoring strategies, tailored for recipient characteristics. Despite recent advances, many challenges remain.
Current treatment options are far from perfect: side effects are frequent. Calcineurin inhibitors form the cornerstone of post-transplant immunosuppressive regimens but may themselves result in nephrotoxicity. Transplants frequently do not function for the lifetime of recipients, with the development of chronic allograft nephropathy a consequence of both immune and non-immune mechanisms. There is very little evidence to guide the management of immunosuppression for those with failing transplants and at the time of re-transplantation.
In this Special Issue of the Journal of Clinical Medicine, we invite you to describe recent advances, novel treatments and the personalisation of immunosuppression in the field of kidney transplantation. We welcome original investigations, review articles and short communications.
Prof. Dr. Sîan Griffin
Dr. Caroline Dudreuilh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- kidney
- transplant
- immunosuppression
- induction, toxicity
- personalisation
- cell therapies
- sensitisation
- monitoring
- chronic allograft nephropathy
- tolerance
